In the Louisiana case, officials contend Janssen executives sent out misleading letters to doctors in the state downplaying Risperdal's links to diabetes and improperly claiming the drug was safer than competing medicines, such as Eli Lilly & Co.'s Zyprexa and AstraZeneca LP's Seroquel.